Logo image of IVN.MI

IVISION TECH SPA (IVN.MI) Stock Fundamental Analysis

BIT:IVN - Euronext Milan - IT0005554784 - Common Stock - Currency: EUR

2.32  -0.05 (-2.11%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to IVN. IVN was compared to 64 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of IVN have multiple concerns. IVN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

IVN had negative earnings in the past year.
In the past year IVN had a positive cash flow from operations.
IVN.MI Yearly Net Income VS EBIT VS OCF VS FCFIVN.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 2M -2M -4M

1.2 Ratios

Looking at the Return On Assets, with a value of -0.04%, IVN is doing worse than 62.50% of the companies in the same industry.
IVN's Return On Equity of -0.13% is on the low side compared to the rest of the industry. IVN is outperformed by 62.50% of its industry peers.
With a Return On Invested Capital value of 2.67%, IVN is not doing good in the industry: 64.06% of the companies in the same industry are doing better.
Measured over the past 3 years, the Average Return On Invested Capital for IVN is below the industry average of 8.65%.
Industry RankSector Rank
ROA -0.04%
ROE -0.13%
ROIC 2.67%
ROA(3y)0.84%
ROA(5y)N/A
ROE(3y)3%
ROE(5y)N/A
ROIC(3y)4%
ROIC(5y)N/A
IVN.MI Yearly ROA, ROE, ROICIVN.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 2 4 6

1.3 Margins

IVN has a Operating Margin (6.07%) which is comparable to the rest of the industry.
In the last couple of years the Operating Margin of IVN has declined.
Looking at the Gross Margin, with a value of 60.19%, IVN is in line with its industry, outperforming 51.56% of the companies in the same industry.
IVN's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 6.07%
PM (TTM) N/A
GM 60.19%
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-10.35%
GM growth 5YN/A
IVN.MI Yearly Profit, Operating, Gross MarginsIVN.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 20 40 60 80

3

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), IVN is destroying value.
The number of shares outstanding for IVN has been increased compared to 1 year ago.
Compared to 1 year ago, IVN has an improved debt to assets ratio.
IVN.MI Yearly Shares OutstandingIVN.MI Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 2M 4M 6M
IVN.MI Yearly Total Debt VS Total AssetsIVN.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

IVN has an Altman-Z score of 1.37. This is a bad value and indicates that IVN is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 1.37, IVN is not doing good in the industry: 65.63% of the companies in the same industry are doing better.
The Debt to FCF ratio of IVN is 14.80, which is on the high side as it means it would take IVN, 14.80 years of fcf income to pay off all of its debts.
IVN has a Debt to FCF ratio (14.80) which is in line with its industry peers.
A Debt/Equity ratio of 0.78 indicates that IVN is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.78, IVN is doing worse than 75.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.78
Debt/FCF 14.8
Altman-Z 1.37
ROIC/WACC0.37
WACC7.27%
IVN.MI Yearly LT Debt VS Equity VS FCFIVN.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 5M

2.3 Liquidity

A Current Ratio of 1.93 indicates that IVN should not have too much problems paying its short term obligations.
IVN's Current ratio of 1.93 is fine compared to the rest of the industry. IVN outperforms 60.94% of its industry peers.
IVN has a Quick Ratio of 1.31. This is a normal value and indicates that IVN is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of IVN (1.31) is better than 65.63% of its industry peers.
Industry RankSector Rank
Current Ratio 1.93
Quick Ratio 1.31
IVN.MI Yearly Current Assets VS Current LiabilitesIVN.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 5M 10M 15M

3

3. Growth

3.1 Past

IVN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -108.76%.
The Revenue has grown by 61.65% in the past year. This is a very strong growth!
IVN shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 87.46% yearly.
EPS 1Y (TTM)-108.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-500%
Revenue 1Y (TTM)61.65%
Revenue growth 3Y87.46%
Revenue growth 5YN/A
Sales Q2Q%96.61%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IVN.MI Yearly Revenue VS EstimatesIVN.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 5M 10M 15M

2

4. Valuation

4.1 Price/Earnings Ratio

Industry RankSector Rank
PE N/A
Fwd PE N/A
IVN.MI Price Earnings VS Forward Price EarningsIVN.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

IVN's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. IVN is cheaper than 90.63% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, IVN is valued a bit cheaper than the industry average as 76.56% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 25.28
EV/EBITDA 8.07
IVN.MI Per share dataIVN.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

IVN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

IVISION TECH SPA

BIT:IVN (6/6/2025, 7:00:00 PM)

2.32

-0.05 (-2.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners1.12%
Inst Owner ChangeN/A
Ins Owners66.68%
Ins Owner ChangeN/A
Market Cap18.10M
Analysts80
Price Target3.37 (45.26%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.18
P/FCF 25.28
P/OCF 5.53
P/B 1.85
P/tB 3.08
EV/EBITDA 8.07
EPS(TTM)0
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.09
FCFY3.96%
OCF(TTM)0.42
OCFY18.08%
SpS1.97
BVpS1.25
TBVpS0.75
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.04%
ROE -0.13%
ROCE 3.69%
ROIC 2.67%
ROICexc 3.12%
ROICexgc 3.8%
OM 6.07%
PM (TTM) N/A
GM 60.19%
FCFM 4.66%
ROA(3y)0.84%
ROA(5y)N/A
ROE(3y)3%
ROE(5y)N/A
ROIC(3y)4%
ROIC(5y)N/A
ROICexc(3y)4.55%
ROICexc(5y)N/A
ROICexgc(3y)5.61%
ROICexgc(5y)N/A
ROCE(3y)5.53%
ROCE(5y)N/A
ROICexcg growth 3Y-9.79%
ROICexcg growth 5YN/A
ROICexc growth 3Y-13.26%
ROICexc growth 5YN/A
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-10.35%
GM growth 5YN/A
F-Score4
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0.78
Debt/FCF 14.8
Debt/EBITDA 2.46
Cap/Depr 117.97%
Cap/Sales 16.64%
Interest Coverage 250
Cash Conversion 105.58%
Profit Quality N/A
Current Ratio 1.93
Quick Ratio 1.31
Altman-Z 1.37
F-Score4
WACC7.27%
ROIC/WACC0.37
Cap/Depr(3y)136.09%
Cap/Depr(5y)N/A
Cap/Sales(3y)20.44%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-108.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-500%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)61.65%
Revenue growth 3Y87.46%
Revenue growth 5YN/A
Sales Q2Q%96.61%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y21.34%
EBIT growth 3Y23.59%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y137.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y297.1%
OCF growth 3YN/A
OCF growth 5YN/A